Shilpa Medicare receives USFDA’s approval for Busulfan Injection

22 Apr 2019 Evaluate

Shilpa Medicare has received US Food and Drug Administration’s (USFDA) approval for its ANDA, Busulfan Injection, 60 mg/10 ml. Busulfan Injection, 60 mg/10 ml is a generic equivalent of reference listed drug (RLD), Busulfex Injection, 60 mg/10 ml, used in the treatment of patients with chronic myelogenous leukemia as recommended in the label approved by USFDA.

According to IQVIA MAT Q4 2018 data, the US market for Busulfan Injection, 60 mg/10 ml is approximately $32.8 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

323.95 -1.00 (-0.31%)
18-Dec-2025 10:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1753.85
Dr. Reddys Lab 1272.55
Cipla 1500.30
Zydus Lifesciences 916.25
Lupin 2111.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×